MarketersMEDIA / Newsroom / Antonin Bukovsky announces his new publication “Former Effective Immunotherapy without Adverse Events Inoperable Epithelial Ovarian Cancers”

Antonin Bukovsky announces his new publication “Former Effective Immunotherapy without Adverse Events Inoperable Epithelial Ovarian Cancers”

Share This Press Release

Prof. Dr. ANTONIN BUKOVSKY, MD, Ph.D. has tried to explain effective cancer immunotherapy without adverse events.

— Prof. ANTONIN BUKOVSKY, MD, Ph.D. an Obstetrics and Gynecology specialist realized that novel therapies without adverse events and prevention of cancer relapses were needed to improve treatment and long-lasting survival of patients with epithelial ovarian cancers (EOCs). For this, he has felt the need to comprehend detailed information of the immune system niche involvement in the homeostasis of all body normal tissues and the host immune niche support of cancer growth in vivo.

Former elimination of the host antibodies blocking T cell effectors by intermittent doses of cyclophosphamide that is exhibiting significant immunomodulatory anticancer effects, facilitation of the immune system reactivity against alloantigens of cancer cells by blood transfusions, and augmentation of anticancer immunity by bacterial toxins, resulted during the subsequent treatment-free period into rejection of advanced inoperable EOCs without any adverse events during the treatment. To help prevent cancer relapses, patients treated for advanced primary epithelial cancers should be considered as candidates for continuously stimulating immune anticancer reactivity by treatments altering cancer stem cells, such as daily metformin and weekly raw shiitake mushroom containing anticancer substance lentinan consumptions.

The reported immunotherapy was accompanied by regeneration of the metastatically altered tissues into healthy conditions, including complete regeneration of the liver and other tissues in abdominal cavity affected by severe EOC metastases, without a need of cytoreductive multivisceral surgery, such as intestinal resection, diaphragm stripping or resection, splenectomy and liver resection, which can have severe consequences.

An otherwise untreated rectal cancer resolved after a severe toxic dermatitis lasting over one week, which was caused by an accidental consumption of an uncooked larger raw shiitake mushroom.

After an in-depth study and analyses of the case studies, Bukovsky understood that long-term survival depends on effective prevention of cancer relapses. A study revealed that oral metformin is that medicine which decreases the risk of cancer and also improves cancer survival. Another study revealed the effective consumption of raw shiitake mushrooms. It was found that daily 2g metformin and weekly consumption of a single larger raw shiitake mushroom in salads prevented malignant recurrences over the next 25 years, with no subsequent signs of dermatitis.

Bukovsky’s research study comes at a time when the cases for EOCs are on the rise globally. This groundbreaking study can be of great use to the medical community trying to find solutions for this unresolved medical condition. Carefully designed modern clinical trials on patients with advanced epithelial malignancies are needed to further investigate the potential of these reported therapies.

For details and Tables of the course of effective advanced inoperable EOCs immunotherapy without cytoreductive surgery and adverse events see free published article at:

http://www.annexpublishers.com/articles/JGR/4102-Former-Effective-Immunotherapy-without-Adverse-Events-of-Inoperable-Epithelial-Ovarian-Cancers-and-a-Prospect-for-the-Immune-Prophylaxis.pdf

Contact Info:
Name: Kherington C. Lewis
Email: Send Email
Organization: Index Of Sciences Ltd
Address: Kemp House, 160 City Road, London EC1V 2NX.UK.
Phone: +44 1442781196
Website: https://indexofsciences.com/

Source URL: https://marketersmedia.com/antonin-bukovsky-announces-his-new-publication-former-effective-immunotherapy-without-adverse-events-inoperable-epithelial-ovarian-cancers/88919984

Source: MarketersMedia

Release ID: 88919984

Subscribe and Receive exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2019 MarketersMEDIA – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).